S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic α-Secretase Activity Acts via Selective Promotion of ADAM-10

Weiping Qin, Lap Ho, Jun Wang et al. · 2009

Read S100A7, a Novel Alzheimer's Disease Biomarker with Non-Amyloidogenic α-Secretase Activity Acts via Selective Promotion of ADAM-10 by Weiping Qin, Lap Ho, Jun Wang et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0004183.txt.

Description

Weiping Qin and colleagues published this Alzheimer's study in PLOS ONE in 2009. Alzheimer's disease is the most common cause of dementia in older people. There is no cure, and there were no early diagnostic tests when this study appeared. So the hunt for a biomarker, a measurable sign of disease, was urgent.

The team studied S100A7, a protein they put forward as a novel biomarker. They report that it acts by selectively boosting ADAM-10, an enzyme that cuts the amyloid precursor protein in the safer, non-amyloid route. One protein thus offers both a possible early sign of disease and a clue to slowing it.

Catalog record

CREATORWeiping Qin, Lap Ho, Jun Wang et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE64 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0004183

Browse the full library · About the Tower of Babel